All In MedTech

Device Trial Radar · NCT04911270

Clinical Decision Support Tool for Vancomycin Dosing in Children

A Pharmacokinetic Study to Evaluate the Use of a Novel Clinical Decision Support Tool, Lyv, in Achieving AUC24/MIC > 400 in Pediatric Patients on Vancomycin

Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

75

Actual

Start

May 9, 2022

Primary completion

Apr 12, 2024

Study completion May 10, 2025

Sponsor

Lead sponsor
University of Maryland, BaltimoreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Center for Translational Medicine at the School of Pharmacy; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
Jun 3, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the pharmacokinetic and pharmacodynamic dosing properties of intravenous vancomycin in pediatric patients using a novel computer decision support (CDS) tool called Lyv. Dosing will be individualized based on AUC24/MIC. The results will be compared to matched historical controls.

Conditions

  • Gram-Positive Bacterial Infections
  • Vancomycin
  • Pharmacokinetics
  • Pharmacodynamics

Interventions

  • Computer Decision Support Tool Intervention GroupDevice

    Computer Decision Support Tool using Bayesian estimation to dose IV vancomycin in pediatric patients using AUC24/MIC

  • Matched Historical ControlsOther

    Vancomycin dosing based on standard hospital methods, with dose adjustments based on vancomycin trough targets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC24/MIC target attainment of vancomycin after first dose using the clinical decision support tool compared to dosing using the current hospital methodTime frame: 2-6 hours post first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Maryland Medical Center

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.